BiotechTube
Home/Tolremo Therapeutics/Stefanie Flückiger-Mangual, PhD
SF

Stefanie Flückiger-Mangual, PhD

CEO

Tolremo Therapeutics

Therapeutic Areas

Oncology

Tolremo Therapeutics Pipeline

DrugIndicationPhase
TT125-802Solid tumors and hematological malignancies (for prevention of resistance)Phase 1

Leadership Team at Tolremo Therapeutics

AC
Alessandra Cesano, MD, PhD
Chief Medical Officer
JC
Jessica Corson
Chief Business Officer
CE
Claudia Escher, PhD
COO
JM
Julie M. Cherrington, PhD
Chair of the Board
View full Tolremo Therapeutics profile